Capital CS Group’s BioNTech BNTX Stock Holding History

Capital CS Group’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,400	Closed	-$357K	–	73
2021 Q3	$357K	Buy	+1,400	New	+$445K	0.33%	51

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Capital CS Group's BNTX Position: Q4 2021 in Review

Capital CS Group sold out of BioNTech (BNTX) in Q4 2021, closing a stake of 1,400 shares — an estimated $357K sold.

Capital CS Group first reported a position in BNTX in Q3 2021 and held it in 1 quarter. The position peaked at $357K in Q3 2021. 354 funds tracked by Wall St. Rank hold BNTX as of Q4 2021.

Capital CS Group reported no remaining BioNTech position as of Q4 2021 after selling out during the quarter.
Capital CS Group sold 1,400 BioNTech shares in Q4 2021, an estimated $357K.
Capital CS Group first reported a position in BioNTech in Q3 2021 and held it in 1 quarter.
Capital CS Group's BioNTech position peaked at $357K in Q3 2021.
354 funds tracked by Wall St. Rank held BioNTech as of Q4 2021.

Based on Capital CS Group's 13F filing for Q4 2021, filed 20 Jan 2022.